Literature DB >> 26605932

Cardiovascular Risk and Sodium-Glucose Cotransporter 2 Inhibition in Type 2 Diabetes.

Julie R Ingelfinger1, Clifford J Rosen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26605932     DOI： 10.1056/NEJMe1512602

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  9 in total

1.  Empagliflozin reduces blood pressure and uric acid in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.

Authors:  Di Zhao; Hui Liu; Pingshuan Dong
Journal:  J Hum Hypertens       Date:  2018-11-15       Impact factor: 3.012

Review 2.  Cardiovascular Safety of Antihyperglycemic Agents: "Do Good or Do No Harm".

Authors:  Antonis A Manolis; Theodora A Manolis; Antonis S Manolis
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 3.  Bringing patient centricity to diabetes medication access in Canada.

Authors:  Judith L Glennie; Katharina Kovacs Burns; Paul Oh
Journal:  Clinicoecon Outcomes Res       Date:  2016-10-17

4.  Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.

Authors:  Gian Paolo Fadini; Benedetta Maria Bonora; Giancarlo Zatti; Nicola Vitturi; Elisabetta Iori; Maria Cristina Marescotti; Mattia Albiero; Angelo Avogaro
Journal:  Cardiovasc Diabetol       Date:  2017-04-04       Impact factor: 9.951

5.  Sustained fasting glucose oxidation and postprandial lipid oxidation associated with reduced insulin dose in type 2 diabetes with sodium-glucose cotransporter 2 inhibitor: A randomized, open-label, prospective study.

Authors:  Ken Kanazawa; Hiroshi Uchino; Fumika Shigiyama; Hiroyuki Igarashi; Kayoko Ikehara; Fukumi Yoshikawa; Shuki Usui; Masahiko Miyagi; Hiroshi Yoshino; Yasuyo Ando; Naoki Kumashiro; Takahisa Hirose
Journal:  J Diabetes Investig       Date:  2019-02-19       Impact factor: 4.232

6.  Protective Effects of Sodium-Glucose Transporter 2 Inhibitors on Atrial Fibrillation and Atrial Flutter: A Systematic Review and Meta- Analysis of Randomized Placebo-Controlled Trials.

Authors:  Daobo Li; Yingying Liu; Tesfaldet Habtemariam Hidru; Xiaolei Yang; Yunsong Wang; Cheng Chen; Ka Hou Christien Li; Yuqi Tang; Yushan Wei; Gary Tse; Yunlong Xia
Journal:  Front Endocrinol (Lausanne)       Date:  2021-03-19       Impact factor: 5.555

7.  High pericoronary adipose tissue attenuation on computed tomography angiography predicts cardiovascular events in patients with type 2 diabetes mellitus: post-hoc analysis from a prospective cohort study.

Authors:  Keishi Ichikawa; Toru Miyoshi; Kazuhiro Osawa; Mitsutaka Nakashima; Takashi Miki; Takahiro Nishihara; Hironobu Toda; Masatoki Yoshida; Hiroshi Ito
Journal:  Cardiovasc Diabetol       Date:  2022-03-18       Impact factor: 9.951

Review 8.  Insulin resistance in cardiovascular disease, uremia, and peritoneal dialysis.

Authors:  Mark Lambie; Mario Bonomini; Simon J Davies; Domenico Accili; Arduino Arduini; Victor Zammit
Journal:  Trends Endocrinol Metab       Date:  2021-07-12       Impact factor: 10.586

9.  Cardiovascular Outcomes with Empagliflozin - News for Type 2 Diabetes Therapy.

Authors:  Baptist Gallwitz
Journal:  Eur Endocrinol       Date:  2016-03-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.